{"log_id": 6502059928496562194, "direction": 0, "words_result_num": 54, "words_result": [{"probability": {"variance": 2e-06, "average": 0.998798, "min": 0.996429}, "location": {"width": 99, "top": 154, "height": 23, "left": 124}, "words": "【不良反应】"}, {"probability": {"variance": 0.003228, "average": 0.963432, "min": 0.839895}, "location": {"width": 91, "top": 184, "height": 23, "left": 154}, "words": "1.胃肠道:"}, {"probability": {"variance": 0.001078, "average": 0.983057, "min": 0.909985}, "location": {"width": 97, "top": 212, "height": 24, "left": 152}, "words": "迟发性腹泻:"}, {"probability": {"variance": 2.2e-05, "average": 0.996769, "min": 0.981432}, "location": {"width": 908, "top": 236, "height": 31, "left": 154}, "words": "腹泻(用药24小时后发生)是本品的剂量限制性毒性反应,在所有听从腹泻处理措施忠告的患者中20%发生严重"}, {"probability": {"variance": 1e-06, "average": 0.998361, "min": 0.997354}, "location": {"width": 40, "top": 273, "height": 22, "left": 119}, "words": "腹泻"}, {"probability": {"variance": 0.001258, "average": 0.98968, "min": 0.781713}, "location": {"width": 905, "top": 295, "height": 30, "left": 156}, "words": "出现第一次稀便的中位时间为滴注本品后第5天。有个别病例出现假膜性结肠炎,其中1例已被细菌学证实(难辨"}, {"probability": {"variance": 1.8e-05, "average": 0.996688, "min": 0.986434}, "location": {"width": 123, "top": 330, "height": 25, "left": 119}, "words": "梭状芽孢杆菌)"}, {"probability": {"variance": 5.8e-05, "average": 0.994794, "min": 0.979739}, "location": {"width": 92, "top": 359, "height": 21, "left": 157}, "words": "恶心与呕吐"}, {"probability": {"variance": 0.007328, "average": 0.979102, "min": 0.596435}, "location": {"width": 370, "top": 384, "height": 25, "left": 159}, "words": "使用止哇药后10%患者仍发生严重恶心及呕吐"}, {"probability": {"variance": 4e-06, "average": 0.99867, "min": 0.994565}, "location": {"width": 112, "top": 416, "height": 23, "left": 156}, "words": "其他胃肠反应"}, {"probability": {"variance": 0.000685, "average": 0.992175, "min": 0.888071}, "location": {"width": 308, "top": 442, "height": 26, "left": 164}, "words": "复泻及/或呕吐伴随脱水症状已有报导"}, {"probability": {"variance": 6e-06, "average": 0.998243, "min": 0.98996}, "location": {"width": 536, "top": 468, "height": 30, "left": 157}, "words": "少于10%的患者发生与本品治疗有关的便秘。少见发生肠梗阻报道"}, {"probability": {"variance": 5e-06, "average": 0.998346, "min": 0.992603}, "location": {"width": 313, "top": 499, "height": 28, "left": 157}, "words": "其他轻微反应如:厌食、腹痛及黏膜炎"}, {"probability": {"variance": 0.001655, "average": 0.979444, "min": 0.898092}, "location": {"width": 86, "top": 531, "height": 22, "left": 155}, "words": "2.血液学"}, {"probability": {"variance": 6.3e-05, "average": 0.996055, "min": 0.952578}, "location": {"width": 902, "top": 552, "height": 32, "left": 157}, "words": "中性粒细胞减少是剂量限制性毒性。78.7%的患者均出现过中性粒细胞减少症,严重者(中性粒细胞计数<500/"}, {"probability": {"variance": 6.2e-05, "average": 0.995821, "min": 0.963228}, "location": {"width": 557, "top": 584, "height": 31, "left": 123}, "words": "mm3)占22.6%在可评价的周期内,18%出现中性粒细胞计数<1000"}, {"probability": {"variance": 0.000214, "average": 0.991149, "min": 0.942508}, "location": {"width": 315, "top": 582, "height": 25, "left": 744}, "words": "其中7.6%中性粒细胞计数<500/mm3,"}, {"probability": {"variance": 0.000115, "average": 0.996512, "min": 0.928932}, "location": {"width": 941, "top": 611, "height": 33, "left": 122}, "words": "中性粒细胞减少症是可逆的和非蓄积的,到最低点的中位时间为8天,通常在第22天完全恢复正常。6.2%的患者(按"}, {"probability": {"variance": 0.001295, "average": 0.98822, "min": 0.756816}, "location": {"width": 939, "top": 639, "height": 34, "left": 127}, "words": "周期为1.7%)出现严重中性粒细胞减少症合并发热。10.3%的患者(按周期为2.5%)出现感染;5.3%的患者(按周期"}, {"probability": {"variance": 0.006518, "average": 0.977884, "min": 0.378568}, "location": {"width": 941, "top": 667, "height": 32, "left": 121}, "words": "为1.1%)出现严重中性粒细胞减少症引起的感染,2例死亡。贫血的发生率为58.7%(其中8%Hb<8g/d,0.9%Hb<65g"}, {"probability": {"variance": 0.008749, "average": 0.959356, "min": 0.607317}, "location": {"width": 455, "top": 698, "height": 31, "left": 125}, "words": "/dl).7.4%的患者(按周期为1.8%)出现血小板减少症"}, {"probability": {"variance": 0.001691, "average": 0.971671, "min": 0.827898}, "location": {"width": 344, "top": 697, "height": 22, "left": 632}, "words": "00000/mm3),(其中0.9%血小板<5000"}, {"probability": {"variance": 0, "average": 0.998451, "min": 0.998451}, "location": {"width": 22, "top": 700, "height": 21, "left": 1040}, "words": "按"}, {"probability": {"variance": 0.004491, "average": 0.982185, "min": 0.518628}, "location": {"width": 929, "top": 723, "height": 34, "left": 127}, "words": "周期为0.2%)。几乎所有患者均在第22天恢复,在上市后使用中,曾报道1例因抗血小板抗体导致外周血小板减少"}, {"probability": {"variance": 0, "average": 0.999135, "min": 0.998158}, "location": {"width": 75, "top": 762, "height": 23, "left": 122}, "words": "症的病例"}, {"probability": {"variance": 6.8e-05, "average": 0.995351, "min": 0.975064}, "location": {"width": 148, "top": 788, "height": 23, "left": 186}, "words": "急性胆碱能综合征"}, {"probability": {"variance": 0.001737, "average": 0.989788, "min": 0.701535}, "location": {"width": 905, "top": 810, "height": 31, "left": 158}, "words": "9%的患者出现短暂严重的急性胆碱能综合征。主要症状为;早发性腹泻及其他症状,如用药后第一个24小时内发"}, {"probability": {"variance": 0.004343, "average": 0.988439, "min": 0.518657}, "location": {"width": 930, "top": 837, "height": 33, "left": 124}, "words": "生;腹痛、结膜炎、鼻炎、低血压、血管舒张、出汗、寒战、全身不适、头晕、视力障碍、瞳孔缩小、流泪、流涎增多"}, {"probability": {"variance": 0, "average": 0.999656, "min": 0.998936}, "location": {"width": 240, "top": 872, "height": 26, "left": 123}, "words": "以上症状于阿托品治疗后消失"}, {"probability": {"variance": 2e-06, "average": 0.99842, "min": 0.996384}, "location": {"width": 75, "top": 902, "height": 22, "left": 186}, "words": "其他作用"}, {"probability": {"variance": 3.9e-05, "average": 0.996113, "min": 0.962275}, "location": {"width": 904, "top": 921, "height": 33, "left": 159}, "words": "早期的反应如呼吸困难、肌肉收缩、痉挛及感觉异常等均有报道。少于10%的患者出现严重乏力,其与使用本品"}, {"probability": {"variance": 0.007086, "average": 0.976566, "min": 0.511932}, "location": {"width": 940, "top": 949, "height": 35, "left": 124}, "words": "的确切关系尚未阐明。常见脱发,为可逆的。12%的患者在无感染或严重中性粒细胞减少症的情况下出现发热。轻度皮"}, {"probability": {"variance": 1.2e-05, "average": 0.998035, "min": 0.985}, "location": {"width": 497, "top": 982, "height": 30, "left": 123}, "words": "肤反应,变态反应及注射部位的反应尽管不常见,但也有报道"}, {"probability": {"variance": 0.012766, "average": 0.953491, "min": 0.676736}, "location": {"width": 122, "top": 1016, "height": 23, "left": 161}, "words": "5.实验室检查"}, {"probability": {"variance": 0.006645, "average": 0.979189, "min": 0.413103}, "location": {"width": 904, "top": 1035, "height": 34, "left": 161}, "words": "血清中短暂、轻至中度转氨酶、碱性磷酸酶、胆红素水平升高的发生率分别为9.2%8.1%和18%(指在无进展"}, {"probability": {"variance": 0.002583, "average": 0.987533, "min": 0.701679}, "location": {"width": 562, "top": 1068, "height": 30, "left": 124}, "words": "性肝转移的患者)。7.3%的患者出现短暂的轻至中度血清肌酐水平升高"}, {"probability": {"variance": 0.018017, "average": 0.922207, "min": 0.689716}, "location": {"width": 91, "top": 1102, "height": 22, "left": 131}, "words": "【禁忌】"}, {"probability": {"variance": 0.000474, "average": 0.987295, "min": 0.901415}, "location": {"width": 342, "top": 1123, "height": 31, "left": 161}, "words": "1.禁用于有慢性肠炎和/或肠梗阻的患者"}, {"probability": {"variance": 0.000713, "average": 0.992161, "min": 0.848215}, "location": {"width": 561, "top": 1149, "height": 34, "left": 159}, "words": "2.禁用于对盐酸伊立替康三水合物或其辅料有严重过敏反应史的患者"}, {"probability": {"variance": 0.019718, "average": 0.954276, "min": 0.468631}, "location": {"width": 232, "top": 1183, "height": 28, "left": 160}, "words": "3.禁用于孕期和哺乳期妇女"}, {"probability": {"variance": 0.002484, "average": 0.985048, "min": 0.770747}, "location": {"width": 347, "top": 1210, "height": 29, "left": 189}, "words": "禁用于胆红素超过正常值上限1.5倍的患者"}, {"probability": {"variance": 7e-06, "average": 0.997976, "min": 0.989846}, "location": {"width": 260, "top": 1240, "height": 28, "left": 189}, "words": "禁用于严重骨髓功能衰竭的患者"}, {"probability": {"variance": 0.002257, "average": 0.983303, "min": 0.795077}, "location": {"width": 309, "top": 1269, "height": 28, "left": 189}, "words": "禁用于WHO行为状态评分>2的患者"}, {"probability": {"variance": 0, "average": 0.999281, "min": 0.998391}, "location": {"width": 99, "top": 1302, "height": 23, "left": 132}, "words": "【注意事项】"}, {"probability": {"variance": 1e-06, "average": 0.999175, "min": 0.99692}, "location": {"width": 350, "top": 1327, "height": 25, "left": 192}, "words": "本品应在有经验的肿瘤专科医生指导下使用"}, {"probability": {"variance": 0.000927, "average": 0.991012, "min": 0.828763}, "location": {"width": 886, "top": 1350, "height": 32, "left": 162}, "words": "2.考虑到不良反应的性质及发生率,对以下患者应在充分权衡治疗带来的好处及可能发生的危险后再选用本药"}, {"probability": {"variance": 0.002063, "average": 0.981361, "min": 0.78797}, "location": {"width": 426, "top": 1383, "height": 26, "left": 174}, "words": "()患者具危险因素,特别是WHO行为状态评分=2"}, {"probability": {"variance": 3.7e-05, "average": 0.996931, "min": 0.965481}, "location": {"width": 889, "top": 1407, "height": 32, "left": 179}, "words": "2)在一些罕见的情况下,患者被认为不愿遵守有关不良反应处理措施的忠告时,(当迟发性腹泻一旦发生,需立"}, {"probability": {"variance": 9e-05, "average": 0.997108, "min": 0.94661}, "location": {"width": 579, "top": 1437, "height": 34, "left": 129}, "words": "即和持续给予大量液体及抗腹泻治疗)。建议医院应对这类患者严格管理"}, {"probability": {"variance": 0.000205, "average": 0.996146, "min": 0.9155}, "location": {"width": 578, "top": 1467, "height": 31, "left": 163}, "words": "3.本品不能静脉推注,静脉滴注时间亦不得少于30分钟或超过90分钟"}, {"probability": {"variance": 0.000354, "average": 0.99178, "min": 0.945705}, "location": {"width": 132, "top": 1502, "height": 24, "left": 191}, "words": "关于迟发性腹泻"}, {"probability": {"variance": 7e-06, "average": 0.998074, "min": 0.989734}, "location": {"width": 898, "top": 1523, "height": 34, "left": 172}, "words": "患者必须了解,在使用本品24小时后及在下周期化疗前任何时间均有发生迟发性腹泻的危险。静脉滴注本品后发"}, {"probability": {"variance": 3e-06, "average": 0.998509, "min": 0.991219}, "location": {"width": 939, "top": 1554, "height": 32, "left": 129}, "words": "生首次稀便的中位时间是第5天,一旦发生应马上通知医生并立即开始适当的治疗。既往接受过腹部/盆腔放疗的患者"}, {"probability": {"variance": 0.000118, "average": 0.996054, "min": 0.94584}, "location": {"width": 939, "top": 1581, "height": 34, "left": 129}, "words": "基础白细胞升高及行为状态评分>2的患者,其腹泻的危险性增加。如治疗不当,腹泻可能危及生命,尤其对于合并中"}], "language": 3}